Scarica l'app Stockscreener
1.19
3.97%
-0.07
Precedente Chiudi:
$1.26
Aprire:
$1.25
Volume 24 ore:
214.77K
Relative Volume:
0.21
Capitalizzazione di mercato:
$1.36M
Reddito:
$815.40K
Utile/perdita netta:
$-14.03M
Rapporto P/E:
-0.00451
EPS:
-264.0465
Flusso di cassa netto:
$-9.68M
1 W Prestazione:
+10.00%
1M Prestazione:
-83.69%
6M Prestazione:
-98.96%
1 anno Prestazione:
-99.61%
Intervallo 1D:
$1.18
$1.25
Intervallo di 1 settimana:
$1.05
$1.44
Portata 52W:
$0.911
$382.50
Onconetix Inc Stock (ONCO) Company Profile
Nome
Onconetix Inc
Settore
Industria
Telefono
513-620-4101
Indirizzo
201 E. FIFTH STREET, CINCINNATI
Compare ONCO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
1.19 | 1.42M | 815.40K | -14.03M | -9.68M | -264.05 |
VRTX
Vertex Pharmaceuticals Inc
|
436.94 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.26 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.41 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.56 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.60 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onconetix Inc Borsa (ONCO) Ultime notizie
Number of shareholders of Onconetix Inc – FWB:J4T - TradingView
Number of shareholders of Onconetix Inc – GETTEX:A42ANX - TradingView
Pretax income of Onconetix Inc – GETTEX:A42ANX - TradingView
Onconetix Inc (ONCO) Stock Price, Quote, News & History - Benzinga
Onconetix reverse split 10-to-1, aimed at Nasdaq $1 bid rule - Stock Titan
Onconetix Sets 1-for-10 Reverse Stock Split Effective - TipRanks
Onconetix (ONCO) enacts 1-for-10 reverse split to support Nasdaq listing - Stock Titan
What's going on in today's session - ChartMill
Onconetix approves 1-for-10 reverse stock split effective May 21 By Investing.com - Investing.com Australia
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Realbotix Provides Update on Nasdaq Listing - Investing News Network
Onconetix, Inc. announces 1-for-10 reverse stock split - marketscreener.com
Onconetix: Split Intended to Enable Co to Maintain Compliance With Minimum Bid Price Requirement of $1/Shr of Common Stk for Continued Listing on Nasdaq Cap Market >ONCO - Moomoo
Onconetix approves 1-for-10 reverse stock split effective May 21 - Investing.com
Realbotix provides update on Nasdaq listing - marketscreener.com
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split - GlobeNewswire
Onconetix (ONCO) stock surges over 23% overnight: Why is it moving? - MSN
Onconetix shares jump 23.65% after clinical study boosts confidence in prostate cancer test Proclarix. - Pluang
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving? - Benzinga
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed ... - Post Register
Onconetix Advances Proclarix Clinical Validation and Market Expansion - TipRanks
Onconetix (ONCO) highlights new Proclarix studies and U.S. PRIME trial - Stock Titan
Onconetix Reports Q1 2026 Progress: Proclarix® Validated in Peer-Reviewed Studies, U.S. PRIME Study Launched, and European Expansion Continues 1 - Minichart
ONCO Technical Analysis | Trend, Signals & Chart Patterns | ONCONETIX INC (NASDAQ:ONCO) - ChartMill
Onconetix, Inc. Q1 2026 Financial Report: Key Risks, Market Strategies, and Forward-Looking Statements - Minichart
Onconetix's Proclarix advances with new studies and U.S. validation study launch, expanding in Europe. - Pluang
Onconetix reports Q1 progress for prostate cancer test Proclarix By Investing.com - Investing.com India
ONCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Onconetix Reports Two Proclarix Publications and U.S. Validation Study in Q1 2026 - geneonline.com
Onconetix reports Q1 progress for prostate cancer test Proclarix - Investing.com
Onconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with Labcorp - Quiver Quantitative
Blood test aims to cut unnecessary prostate biopsies, now in U.S. study - Stock Titan
Onconetix Reports Q1 2026 Progress at Proteomedix AG, - GlobeNewswire
Onconetix, Inc. 1Q 2026: Revenue $21.46K, EPS ($6.71) — 10-Q Summary - TradingView
Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Onconetix (NASDAQ: ONCO) posts Q1 loss, warns on going concern amid Realbotix deal - Stock Titan
Onconetix, Inc. (ONCO) Eps Diluted (TTM) - Zacks Investment Research
How to Buy Onconetix (ONCO) Stock in Canada - Moomoo
[EFFECT] Onconetix, Inc. SEC Filing - Stock Titan
TradingKey - TradingKey
Onconetix (ONCO) registers 25M shares for resale under Keystone ELOC - Stock Titan
Number of shareholders of Onconetix, Inc. – NASDAQ:ONCO - TradingView
Number of shareholders of Onconetix Inc – FWB:J4T1 - TradingView
Onconetix (ONCO) adds counsel legal opinion in S-1 Amendment - Stock Titan
Onconetix (ONCO) registers 38.8M resale shares tied to PIPE warrants - Stock Titan
Onconetix Shareholders Approve Flexible Reverse Stock Split Authorization - The Globe and Mail
Onconetix Stock Short Interest Falls to 33.12% - Quiver Quantitative
Onconetix stock skyrockets after Realbotix ships Vinci-equipped robot to Ericsson - MSN
Onconetix (NASDAQ: ONCO) investors back reverse stock split, adjournment - Stock Titan
Onconetix Inc (ONCO) - MSN
Onconetix (NASDAQ: ONCO) files S-1 for 25M-share Keystone equity line resale - Stock Titan
Onconetix Inc Azioni (ONCO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):